Litigation Details for TARO PHARMACEUTICALS U.S.A., INC. v. GLENMARK PHARMACEUTICALS LTD. (D.N.J. 2018)
✉ Email this page to a colleague
TARO PHARMACEUTICALS U.S.A., INC. v. GLENMARK PHARMACEUTICALS LTD. (D.N.J. 2018)
Docket | ⤷ Sign Up | Date Filed | 2018-08-08 |
Court | District Court, D. New Jersey | Date Terminated | 2019-11-26 |
Cause | 35:271 Patent Infringement | Assigned To | John Michael Vazquez |
Jury Demand | None | Referred To | Mark Falk |
Patents | 8,277,780; 8,715,624 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in TARO PHARMACEUTICALS U.S.A., INC. v. GLENMARK PHARMACEUTICALS LTD.
Details for TARO PHARMACEUTICALS U.S.A., INC. v. GLENMARK PHARMACEUTICALS LTD. (D.N.J. 2018)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
0000-00-00 | External link to document | |||
2018-08-08 | 1 | Complaint | infringement of United States Patent Nos. 8,277,780 (the “’780 patent”) (attached as Exhibit A) and …must include, among other things, the patent number of any patent that claims the drug or a method of … Taro’s Patents Covering Topicort® 27. The United States Patent & Trademark Office…the ’780 and ’624 patents with the FDA. The FDA has published the ’780 and ’624 patents in the Orange Book…expiration of the ’780 patent will constitute an act of infringement of the ’780 patent. 39. On | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |